Global Arthritis Monoclonal Antibodies Markets 2022-2026 & 2031: Remicade, Humira, Enbrel, Rituxan, Orencia, Actemra, Simponi, Cimzia, Remsima – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Arthritis Monoclonal Antibodies Global Market Report 2022: By Drug, By Application, By End-Use” report has been added to ResearchAndMarkets.com’s offering. Arthritis Monoclonal Antibodies Global Market Report 2022 provides the strategists, marketers and senior management with the critical information they need to assess the global arthritis monoclonal antibodies (mab’s) market. This report focuses on … [Read more…]

Heavy Metal Poisoning Drugs in Development 2022, by Stages, Target, MoA, RoA, Molecule Type and Key Players – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Heavy Metal Poisoning Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update” report has been added to ResearchAndMarkets.com’s offering. The pipeline guide provides comprehensive information on the therapeutics under development for Heavy Metal Poisoning (Toxicology), complete with analysis by stage of development, drug target, mechanism of action … [Read more…]

Echosens and Novo Nordisk Announce Partnership to Increase Awareness and Advance Early Diagnosis of NASH

PARIS & BAGSVÆRD, Denmark–(BUSINESS WIRE)–#NAFLD—Echosens, a high-technology company offering liver diagnostic solutions, and Novo Nordisk A/S, a leading global healthcare company, today announced a partnership to advance early diagnosis of non-alcoholic steatohepatitis (NASH) and increase awareness of the disease among patients, healthcare providers and other stakeholders. NASH is a chronic metabolic liver disease that affects … [Read more…]

Battery Ventures Makes Majority Investment in Titian Software

Deal will fuel continued growth at U.K.-based, sample-management software company, which improves research processes for critical biotech, pharmaceutical and academic organizations BOSTON–(BUSINESS WIRE)–#industrialtech–Battery Ventures, a global, technology-focused investment firm, announced a significant, majority investment in Titian Software Ltd., a U.K. company that develops innovative sample-management software and related services for life-sciences laboratories. Specific terms were … [Read more…]

Congenica Appoints Robert Denison as CEO

CAMBRIDGE, England–(BUSINESS WIRE)–Congenica, a digital health company that enables precision medicine through its world-leading diagnostic decision support platform for genomic data, today announces the appointment of Robert Denison as Chief Executive Officer (CEO). He will also join the Board of the company. Rob has a strong history of growing businesses ranging from start-ups through to … [Read more…]

Galderma Announces Positive Data From Phase III Trial, Demonstrating Efficacy and Safety of nemolizumab in Patients with Prurigo Nodularis

Prurigo nodularis is a rare, potentially debilitating, inflammatory skin disease characterized by disfiguring skin nodules often covering extensive areas of the body, and an intense and chronic itch There are currently no approved therapeutic options Nemolizumab is a first-in-class investigational monoclonal antibody that blocks the signaling of IL-31, a key neuroimmune cytokine involved in the … [Read more…]

Trastuzumab Deruxtecan Type II Variation Application Validated by EMA for Patients with HER2 Low Metastatic Breast Cancer with HR Positive and HR Negative Disease

Application based on DESTINY-Breast04 results that showed Daiichi Sankyo and AstraZeneca’s trastuzumab deruxtecan demonstrated superior progression-free and overall survival versus chemotherapy TOKYO & MUNICH–(BUSINESS WIRE)–Daiichi Sankyo (TSE: 4568) today announced that the European Medicines Agency (EMA) has validated the Type II Variation application for trastuzumab deruxtecan as monotherapy for the treatment of adult patients with … [Read more…]

Poxel Announces Results from June 21, 2022 Ordinary Annual and Extraordinary General Meeting

Shareholders approved all proposed resolutions LYON, France–(BUSINESS WIRE)–POXEL SA (Euronext: POXEL – FR0012432516), a clinical stage biopharmaceutical company developing innovative treatments for chronic serious diseases with metabolic pathophysiology, including non-alcoholic steatohepatitis (NASH) and rare metabolic disorders, today announces that it held its ordinary annual and extraordinary general meeting of shareholders on June 21, 2022. The … [Read more…]

InnoCare Announces First Patient Dosed in Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China

BEIJING–(BUSINESS WIRE)–InnoCare Pharma (HKEX: 09969), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced today that the first patient has been dosed in clinical trial of the Company’s novel SHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189 in China. ICP-189 is a potent and selective oral … [Read more…]

Quidel Corporation and the American Heart Association join forces to Advance Education and Awareness of Heart Disease in San Diego County

The three-year, $750,000 commitment is expected to improve overall health and save lives SAN DIEGO–(BUSINESS WIRE)–QuidelOrtho Corporation (NASDAQ: QDEL) (“QuidelOrtho”) — QuidelOrtho announces that its subsidiary, Quidel Corporation, is collaborating with the American Heart Association, the leading voluntary health organization devoted to a world of longer and healthier lives, to improve the health of San … [Read more…]